NRXP

NRX Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website nrxpharma.com
Employees(FY) -
ISIN US6294442099

Performance

+25.0%

+22.45%

-8.54%

-50.82%

-67.39%

YTD

-63.3%

Profile

NRx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company has a joint Agreement with Nephron Pharmaceuticals, Inc. to develop intravenous ketamine to treat suicidal depression. The company was founded in 2015 and is based in Wilmington, Delaware.

Advanced Technical Analysis

Technical Analysis of NRXP 2024-12-20

The Moving Average Score of 63 indicates a bullish sentiment, while the Oscillators Score of 43 and Technical Score of 53 suggest a more neutral outlook. Overall, the mixed scores imply a cautiously optimistic sentiment in the stock, with the moving averages providing the strongest support for potential upward movement.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NRXP

Stock Rank

Recent News & Updates

2024-11-25 19:03
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024(Prnewswire)
2024-11-24 19:03
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled 'Quality Assurance of Depression Ratings in Psychiatric Clinical Trials'(Prnewswire)
2024-11-18 13:03
NRX Pharmaceuticals Inc (NRXP) Q3 2024 Earnings Call Highlights: Significant Reduction in ...(Yahoo Finance)
2024-11-18 03:05
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer(Prnewswire)
2024-11-14 03:05
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update(Prnewswire)
2024-11-12 19:03
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024(Prnewswire)
2024-11-07 03:06
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024(Prnewswire)
2024-10-30 19:00
NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule(Globenewswire)
2024-10-29 19:47
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics(Prnewswire)
2024-10-22 20:30
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024(Globenewswire)
2024-10-12 05:18
NRx Pharmaceuticals Leadership Shift and Strategic Governance Decisions(Yahoo Finance)
2024-10-02 18:55
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic(Prnewswire)
2024-09-29 19:00
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)(Prnewswire)
2024-09-10 19:55
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com(Prnewswire)
2024-09-02 19:55
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024(Prnewswire)
2024-08-25 19:55
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics(Prnewswire)
2024-08-14 04:01
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update(Prnewswire)
2024-08-13 04:01
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024(Prnewswire)
2024-08-12 19:30
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds(Prnewswire)
2024-07-28 20:35
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine)(Prnewswire)
2024-07-28 20:30
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (Nasdaq:NRXP) Announce Arbitration Order Enabling HOPE Therapeutics Spinoff(Prnewswire)
2024-06-30 20:07
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter(Yahoo Finance)
2024-06-27 20:07
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing(Prnewswire)
2024-06-19 20:30
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024(Prnewswire)
2024-06-17 20:30
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors(Prnewswire)
2024-06-09 20:30
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter(Yahoo Finance)
2024-05-27 20:30
NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipola(Prnewswire)
2024-05-14 08:57
NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024(Investorplace)
2024-05-14 04:01
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update(Prnewswire)
2024-05-07 21:55
NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update(Yahoo Finance)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.